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Statins are widely used to lower cholesterol and prevent complications of cardiovascular
disease. The non-lipid lowering (pleiotropic) effects of statins may also have applications to
the management of infections. These include effects on endothelial function, inflammation
and coagulation pathways. Several observational studies have shown a significant reduction
in 30-day mortality associated with prior statin therapy in hospitalised patients with sepsis
and community acquired pneumonia.
This article explores the evidence for statins as novel therapy in community acquired pneu-
monia. Experimental and animal studies suggest statins attenuate acute lung injury by modu-
lating neutrophil function, reducing pro-inflammatory cytokine release and reducing vascular
leak. Statins reduce endothelial dysfunction and have anti-thrombotic effects that improve
outcome from pneumonia and sepsis in animal models. Clinical studies have provided conflict-
ing results, but many suggest that statins may have a role in preventing pneumonia, or
improving prognosis in hospitalised patients with community-acquired pneumonia.
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Community acquired Pneumonia is the most common infec-
tious disease requiring hospitalisation in western countries
accounting for approximately 100,000 hospital admissions in
England during 2004e2005. Hospital admissions for pneu-
monia are rising, particularly in elderly patients.1
The inpatient mortality for community acquired pneu-
monia is around 10%.2e5 This has not changed since the
widespread introduction of antibiotics in the 1950’s and
there are still no established therapies beyond antibiotics
for treatment of community acquired pneumonia.6
Mortality from community-acquired pneumonia is
multifactorial, but is linked to excessive systemic and
pulmonary inflammation, acute lung injury, vascular
dysfunction and coagulopathy.2,7
Statins lower cholesterol through competitive inhibition
of the enzyme HMG co-A reductase. Landmark studies such
as the Scandinavian Simvastatin Survival Study (4S),8
Cholesterol and Recurrent Events (CARE),9 Long-term
Intervention with Pravastatin in Ischaemic Heart Disease
(LIPID)10 and the West of Scotland Coronary Prevention
Study (WOSCOPS)11 have demonstrated that statin drugs
are associated with reduced mortality from ischaemic heart
disease and stroke, for which hypercholesterolaemia is
a major risk factor.12,13 However, the observation that the
protective effects of statins were significantly greater than
that expected from the lowering of cholesterol alone led to
speculation that statins may have other effects. Statins
have now been shown to have multiple anti-inflammatory
and anti-thrombotic effects, with potential applications
beyond the cardiovascular system.14e18
There is growing evidence that these effects may be of
therapeutic benefit in patients with community acquired
pneumonia. The purpose of this review is to discuss the
non-lipid lowering (pleiotropic) effects of statins, and their
potential application to the management of community
acquired pneumonia.
Search strategy
The authors conducted a systematic review of the PubMed
database up to June 2009 using search terms “Pneumonia”,“sepsis”, “infection”, “inflammation” with terms “statin(s)”,
“HMG-coAreductase inhibitors”.Thesearchwassupplemented
by reviewing reference lists and the authors personal files.
The pleiotropic effects of statins
Alongside its effects on cholesterol biosynthesis, statins
have now been shown to have effects on endothelial
function in addition to anti-thrombotic, anti-inflammatory
and immunomodulatory effects.19e25 HMG-Co A reductase
controls the rate limiting step in cholesterol biosynthesis-
the conversion of 3-hydroxy-3-methyl-glutaryl-CoA to
mevalonic acid. Many of the non-lipid lowering effects of
statins are attributed to the inhibition of mevalonic acid
synthesis and the subsequent reduction in isoprenoid
synthesis (Fig. 1). Multiple cellular processes are reliant on
intracellular signalling molecules such as Rho, Ras, Rap and
Rab (Fig. 1). These small GTP binding proteins require iso-
prenylation in order to function as intracellular messen-
gers. By inhibiting the production of isoprenoid
intermediates, statins inhibit these pathways leading to
multiple effects on inflammatory cell signalling. These
effects have been extensively reviewed.26,27 It is also
thought that interaction with peroxisome proliferator-
activated receptors (PPAR) are necessary for many of the
pleiotropic effects of statins.28 Some of the known effects
on immune cell function relevant to community acquired
pneumonia are summarised in Fig. 2.
Endothelial dysfunction and overwhelming systemic
inflammation have been proposed as major mechanisms for
poor outcome in patients with sepsis and pneumonia.
Through the effects described above, statins may have
a role in improving vascular function and reducing inflam-
mation in these diseases.
Potential mechanisms of the beneficial effects of
statins
The effects of statins in experimental models are diverse,
and which of these effects may be responsible for the
benefit observed in clinical studies is not clear. Here we
discuss some of the pleiotropic effects of statins focussing
on how they may influence pneumonia outcome.
Figure 1 Mechanism of action of statins. Abbreviations:
3-HMG-CoAZ 3-hydroxy-3-methyl-glutaryl-CoA GGPPZ
geranylgeranylpyrophosphate. FFPZ farnesylpyrophosphate.
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Acute lung injury is a disorder characterised by diffuse
endothelial injury and increased capillary permeability.29
Damage to the pulmonary capillary endothelial barrier
leads to exudation of protein fluid into the alveolar space
leading to non-cardiogenic pulmonary oedema.29,30 Lung
injury is mediated by the action of macrophages and
neutrophils with a key contribution from the pro-inflamma-
tory cytokines and proteases, particularly matrix metal-
loproteinases (MMP).29e32 Of the pro-inflammatory
cytokines, TNF-alpha and interleukin-1 are critical, as is the
contribution of triggering receptor expression on myeloid
cells 1 (TREM-1).29e34 Coagulation pathways are central to
the pathogenesis of acute lung injury and are discussed in
detail later. The critical role of Toll-like receptor 4 in regu-
lating acute lung injury has recently been established.33 The
small GTPases Rho and Rac, discussed early as targets of
statin effects, regulate the endothelial barrier including
effects on the actin cytoskeleton and cell to cell adhesion.34
Statins therefore have multiple potentially beneficial
effects on acute lung injury. In vitro, statins have been
found to attenuate pro-inflammatory cytokine release,
including TNF-alpha.35 Effect on macrophages include
decreased cytokine and chemokine release, reduced MMP
production and altered responses to lipopolysaccharide.36
The diverse effects on neutrophils are discussed below.
Statins also appear to reduce endothelial permeability in
vitro, and in vivo. In one study of acute lung injury induced
by intratracheal lipopolysaccharide administration, pre-
treatment with pravastatin protected mice against acute
lung injury.37 Pravastatin treated mice had significantly less
vascular leak and pulmonary infiltration compared tountreated mice.37 Similar findings were reported in rats,
where systemic inflammation was provoked by superior
mesenteric artery occlusion and reperfusion, with rats
treated with simvastatin having significantly higher PaO2,
less neutrophilic lung inflammation and less vascular leak.38
Human studies have been lacking to date, but a recent key
study has investigated the effects of simvastatin on lung
injury caused by LPS administration to healthy volun-
teers.30 Shyamsundar et al. found a significant reduction in
neutrophil influx into the lung, with reduced alveolar
concentrations of TNF-alpha, CRP and matrix metal-
loproteinases.30 These effects appeared to be partly
mediated through reduced macrophage NFkB nuclear
translocation in statin treated subjects.Modulation of neutrophil function
Statins have powerful effects on neutrophils and there is
now experimental evidence from a murine model of pneu-
monia that these effects attenuate pulmonary inflamma-
tion. In a study by Fessler et al., mice were treated with
lovastatin and exposed to lipopolysaccharide (LPS) to
simulate pneumonia.39 In the treated mice, there was
a significant reduction in neutrophil influx into the lungs,
decreased neutrophil chemotaxis and reduced levels of pro-
inflammatory cytokines in bronchoalveolar lavage fluid. In
a parallel model of Klebsiella pneumoniae pneumonia,
statin treatment attenuated bacterial killing.
All of these processes were reversible with the admin-
istration of mevalonic acid (see Fig. 1) bypassing inhibition
by statins and proving that the observed effects are the
result of effects of statins on the mevalonic acid pathway.39
A further study in mice by Erkkila et al. found an
increase in pulmonary inflammation in a mouse model of
pneumonia induced by Chlamydophila pneumoniae.40 Sim-
vastatin treatment was associated with reduced numbers of
viable organisms. The results of this study appear to be in
contrast to those of Fessler et al. One important consid-
eration is that different statin drugs may have different
effects. The same group repeated their experiments using
pravastatin and found that, although they also saw
increased pulmonary inflammation, pravastatin did not
decrease pulmonary bacterial load.41
Statins have been shown to increase neutrophil
apoptosis.42 Neutrophil apoptosis is a critical mechanism in
the resolution of inflammation and may aid recovery from
pneumonia. Other important effects of statins on neutro-
phil function include decreased expression of LFA-1 and
ICAM-1,43 decreased myeloperoxidase production,44
reduction in neutrophil reactive oxygen species,45 effects
on neutrophil migration46 and on angiotensin-II type 1
receptor expression.45 In humans, simvastatin has been
shown to reduce superoxide production from neutrophils in
ICU patients with sepsis.47 Further studies are needed to
delineate the different immunomodulatory effects of sta-
tins and their relevance to pneumonia.
Anti-thrombotic effects
Coagulopathy is a central feature of pneumonia and other
forms of acute lung injury.48e50 Intra-alveolar fibrin
Figure 2 Selected effects of statins on inflammatory cells and mediators. Abbreviations: APCZ antigen presenting cell,
TNFZ tumour necrosis factor, ILZ interleukin, MHCZmajor histocompatibility complex, BALZ bronchoalveolar lavage.
1084 J.D. Chalmers et al.deposition is a characteristic feature of many inflammatory
lung diseases and may serve a physiological purpose in lung
infection by sealing areas in which the alveolar-epithelial
barrier is compromised.49 When widespread and persistent
these processes are highly damaging and are characteristic
of adult respiratory distress syndrome, a complication of
pneumonia with a high mortality rate. Systemic coagulop-
athy is also evident in pneumonia and sepsis.51 Therefore
therapies with anticoagulant properties may be a potential
treatment for pneumonia.52 Statins have a number of
important anti-thrombotic effects of relevance to cardio-
vascular disease. Statins inhibit the production of throm-
boxane A2 which promotes platelet aggregation in addition
to vasoconstriction.53 As discussed below, statins have
a marked effect on nitric oxide and this mechanism has
been shown to be responsible for reducing platelet acti-
vation.54 Statins reduce the expression of plasminogen
activator inhibitor-1 and thereby increase tissue plasmin-
ogen activator, aiding fibrinolysis.55
An important role of statins appears to be in increasing
the expression of thrombomodulin by endothelial cells.56
This glycoprotein serves an important physiological role in
binding thrombin. When bound, thrombin loses its procoa-
gulant properties and instead activates protein C. The
effects of activated protein C as an anti-inflammatory andanti-coagulant agent in sepsis have been extensively
described.52,57 During sepsis, thrombomodulin expression is
downregulated by inflammatory cytokines. Statins have
been shown to increase thrombomodulin expression via
a mechanism dependant on nitric oxide. In the study by Shi
et al., endothelial cells exposed to TNF-alpha had signifi-
cantly reduced expression of thrombomodulin, expression
that was restored by statins.56
Whether modulation of the coagulation and fibrinolysis
pathways by statins has therapeutic benefit in humans with
pneumonia is not yet known. The major effects of statins on
the coagulation pathways are shown in Fig. 3.
Effects on vascular function
Nitric oxide is a key mediator in sepsis, causing vasodilation
through relaxation of vascular smooth muscle.58 Nitric
oxide is thought to be beneficial to some degree as it has
a role in mediation of inflammation.59 However, wide-
spread vasodilatation leads to organ hypoperfusion and the
clinical syndrome of septic shock. Statins have emerged as
an important inhibitor of nitric oxide production with
relevance to the management of sepsis.
Nitric oxide (NO) production from L-Arginine is mediated
by nitric oxide synthase (NOS). This exists in two isoforms-
Figure 3 Major effects of statins on a simplified representation of platelet activation, coagulation and fibrinolysis pathways.
Components of the pathway thought to be inhibited by statins are shaded in grey. Components thought to be increased by statins
are highlighted in bold. Abbreviations: vWFZ von willebrand factor. PAFZ platelet activating factor. PF-4Z Platelet factor 4.
ADPZ adenosine diphosphate. TXA2Z thromboxane A2. TFPIZ Tissue factor pathway inhibitor. tPAZ Tissue plasminogen acti-
vator. PAI-1Z plasminogen activator inhibitor 1.
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thelium under normal condition and iNOS, inducible nitric
oxide.60 Endothelial dysfunction during sepsis leads to a loss
of eNOS produced NO but an increase in iNOS activity.61
Increased iNOS relative to eNOS has been documented
during sepsis in humans and animals and is associated with
the progression of sepsis.62 iNOS appears critical, as iNOS
deficient mice are resistant to LPS induced mortality.63
Treating vascular dysfunction induced by changes in
nitric oxide expression is more complicated than it first
appears. Therapeutic trials with the non-selective NOS
inhibitor NG-methyl-L-arginine have been disappointing64
and mice studies in which eNOS was over-expressed
showed an improved survival in an LPS model of sepsis.65
Most, but not all studies, suggest that suppression of
nitric oxide itself is unhelpful and a therapy to restore the
balance between eNOS and iNOS is desirable.
Statins have been shown to increase the half-life of eNOS
inendothelial cells.66 A key role for statin effects oneNOSare
suggested by the absence of a beneficial effect of statins on
inflammation in eNOS deficient mice.67 Statins however,
decrease, rather than increase the production of nitric oxide
(measured as plasma nitrate concentration) because they
decrease iNOS mediated nitric oxide production. This
reduction in a ratmodel of sepsiswas shown to correlatewith
an improved response to vasopressor treatment.68 This
suggests that statins have an important effect in reducing
iNOS expression by endothelium during sepsis.
Human studies also suggest that statin pre-treatment can
attenuate endothelial dysfunction and improve responses to
vasoconstrictors. In one study, Pleiner and colleagues rand-
omised healthy volunteers to receive 80 mg of simvastatin orplacebo for 4 days prior to infusion of LPS into the forearm to
cause transient acute inflammation. The results showed
a decreased in endothelial dysfunction in the statin treated
group and a superior response to noradrenaline- mirroring
the findings of the animal studies.69
These effects suggest that statin may reduce the severity
of septic shock and improve the response to vasopressors
primarily through nitric oxide in patients with sepsis.
Disruption of the alveolar epithelial barrier and
increased capillary endothelial permeability is an impor-
tant component of acute lung injury.70 Important regulators
of these phenomena include zinc homeostasis, PPAR sig-
nalling, effects of extracellular ATP and the role of TNF-
alpha and heat shock protein 90.70 Statins have been shown
to have powerful effects on the lung vasculature, attenu-
ating LPS induced vascular leak with effects on the actin
cytoskeleton of vascular endothelial cells helping to sta-
bilise the alveolar epithelial barrier and reduce fluid leak in
acute lung injury.71Reduced cardiovascular risk
Statins reduce the risk of cardiovascular events, including
myocardial infarction, through their effects of cholesterol,
but also through effects on endothelial function, throm-
bosis and inflammation.8e25
Patients with pneumonia are known to be at increased
cardiovascular risk72e75 (and as many as 25% of patients
failing to respond to treatment were found to have acute
myocardial infarction in one study75). Nearly 50% of all
deaths in patients with pneumonia, and more than a quarter
1086 J.D. Chalmers et al.of deathswithin 30 days are related to co-morbidities such as
vascular disease, rather than directly due to pneumonia.2 It
is therefore plausible that the reduced 30-day mortality
observed in cohort studies may simply reflect a lower inci-
dence of cardiovascular events. A detailed discussion of the
mechanisms of cardiac dysfunction in sepsis is beyond the
scope of this review, and have been discussed in detail
elsewhere.76 It is known, however that even in adequately
resuscitated patients with sepsis, impaired left ventricular
function and diastolic dysfunction are observed.77,78 In
cellular and animal models, sepsis provokes depressed
myocyte activity and reduces left ventricular ejection
fraction.79,80
Statins appear to have a cardioprotective effect in animal
models of sepsis, with one study showing preserved cardiac
function as assessed by echocardiography and isolated heart
preparations in mice with experimental sepsis.81
Fig. 4 summarises the proposed beneficial effects of
statins in experimental and animal models.
Clinical studies of statin use in community
acquired pneumonia
Prevention of pneumonia
Investigators hypothesised that through the effects dis-
cussed above, prior statin use may be associated with
a reduced risk of developing pneumonia. The association
between statin use and pneumonia has now been investi-
gated in a number of large databases.
Table 1 summarises the 4 clinical studies to date that
have investigated the role of statins in preventing
pneumonia.
Van De Garde et al. performed a case control study in
more than 20,000 diabetic patients identified using the
General Practice Research Database (GPRD), a large data-
base containing medical records of approximately 6.5% of
the population of England and Wales.82 The study matched
4719 pneumonia cases with 15322 patients without pneu-
monia and found an odds ratio of 0.49 (0.35e0.69) sug-
gesting a powerful protective effect of statins after
adjusting for confounders.82
Schlienger et al. further analysed the GPRD database by
matching 1253 cases of pneumonia with 4838 matchedFigure 4 Possible mechanisms of the beneficial effecontrol patients. The study found that use of statins was
associated with a reduced risk of fatal pneumonia OR 0.47
(0.25e0.88) but found no significant effect on development
of uncomplicated pneumonia.83
Recently Myles et al. confirmed a similar effect. Using
an alternative primary care research database (the health
improvement network (THIN) database) they matched
3709 pneumonia cases with 22,174 matched controls and
found an Odds ratio of 0.78 (0.65e0.94) for development
of CAP. They have subsequently shown a reduced risk
of short and long term mortality following pneumonia
in patients treated with statins using the same
database.84,86
Each of these studies has significant limitations inherent
to retrospective case control studies. The studies rely on
the accuracy of pneumonia diagnosis made by primary care
physicians. In addition, although the analyses were
adjusted for some potential confounders such as vaccina-
tion status and use of other medications, other potential
confounders were not available from these databases.
A recent study by Dublin et al. attempted to control for
more of these potential confounders.85 They studied a large
population of elderly patients (aged >65 years) from a large
administrative database in the United States. Additional
safeguards to ensure accuracy were used, such as reviewing
chest radiograph reports to ensure correct diagnosis of
pneumonia and the analysis was adjusted for a number of
other factors not available in previous databases, such as
functional status. The results of this study did not confirm
the previous reports. In the Dublin study, statin use
appeared to predispose to, rather than protect against
pneumonia. In the minimally adjusted model, statin use
had a odds ratio of 1.13 (0.95e1.34), while in the fully
adjusted model statin use had a odds ratio of 1.26
(1.01e1.56). The authors speculate that the exclusion of
nursing home residents, immunosuppressed patients and
other high risk groups may have exposed a “healthy user
bias” in previous studies.85Prior statin use and outcome in hospitalised
patients with community acquired pneumonia
Statins have not only been implicated in preventing the
development of pneumonia but also in improving thects of statins in community acquired pneumonia.
Table 1 Studies of Statin use to prevent the development of community acquired pneumonia. Abbreviations: GPRDZGeneral
Practice Research Database; THINZ The Health Improvement Network; CAPZ community-acquired pneumonia.
First Author (year) Population Disease N Outcome OR (95% CI)
Van De Garde (2005)82 GPRD, UK CAP 4719 CAP cases
15322 controls
Development of CAP 0.49 (0.35e0.69)
Schlienger (2007)83 GPRD, UK CAP 1253 CAP cases
4838 controls
Development of fatal
pneumonia
0.47 (0.25e0.88)
Myles (2009)84 THIN database, UK CAP 3709 CAP cases
22174 controls
Development of CAP 0.78 (0.65e0.94)
Dublin (2009)85 Group Health
database, USA
CAP 1125 CAP cases
2235 controls
Development of CAP 1.26 (1.01e1.56).
Statins in community acquired pneumonia 1087prognosis of pneumonia and sepsis in hospitalised patients
(Table 2).
A prospective study of 361 patients in 2004 found
a decreased incidence of severe sepsis and a lower ICU
admission rate in patients with sepsis pretreated with sta-
tins (predominantly simvastatin). More than 50% of patients
in this study had pneumonia and this study provided the
first prospective evidence that statins may improve
outcome in pneumonia.87
Subsequently, confirmation of this effect in a community
acquired pneumonia population was found in a retrospec-
tive study of predominantly elderly male patients in theTable 2 Clinical Studies of the effect of prior statin use on out
First Author (year) Population Disease N
Liappis (2001)100 USA Bacteraemia 388
Fernandez (2005)97 Spain Sepsis (ICU) 438
Kruger (2006)98 Australia Bacteraemia 438
Schmidt (2006)101 Germany Sepsis (ICU) 120
Almog (2004)87 Israel Sepsis 361
Mortensen (2005)88 USA CAP 787
Hackam (2006)96 Canada Sepsis 141,487
Thomson (2006)102 Denmark Bacteraemia 5177
Majumdar (2006)91 Canada CAP 3415
Yang (2007)99 Taiwan Sepsis 763
Mortensen (2007)90 USA Sepsis 3018
Mortensen (2008)89 USA Pneumonia/
Influenza
8652
Chalmers (2008)94 UK CAP 1269
Thomson (2008)95 Denmark CAP 29,900United States. This demonstrated dramatically improved
30-day mortality in patients pre-treated with statins (OR
0.36 95% Confidence interval 0.14e0.92).88 The authors
have subsequently published retrospective data showing
a decrease in 30-day mortality from pneumonia and influ-
enza in over 8000 elderly male patients,89 and similarly
a reduction in 30-day mortality OR 0.48 (95% CI 0.36e0.64)
in over 3000 patients with sepsis of any cause.90 These
studies do however, suffer from limitations inherent to
retrospective design.
There was therefore healthy scepticism about the
effect of statins.91 Subsequently, a study derived fromcome in hospitalised patients with sepsis and pneumonia.
Design Outcome OR (95% CI)
Retrospective
cohort
Survival 7.6 (1.01e58)
Retrospective
cohort
In-hospital mortality 2.30 (1.08e4.89)
Retrospective
cohort
In-hospital mortality 0.39 (0.17e0.91)
Retrospective
cohort
28 day mortality 0.53 (0.29e0.99)
Prospective
observation
28 day mortality 0.43 (0.13e1.38)
Severe sepsis 0.13 (0.03e0.52)
Retrospective
cohort
30-day mortality 0.36 (0.14e0.92)
Retrospective
database
Fatal Sepsis 0.75 (0.61e0.93)
Retrospective
database
30-day mortality 0.93 (0.66e1.30)
180-day mortality 0.44 (0.24e0.80)
Prospective
observation
Composite in-hospital
mortality
or ITU admission
1.10 (0.76e1.60)
Retrospective
cohort
30-day mortality 0.95 (0.53e1.68)
Retrospective
database
30-day mortality 0.48 (0.36e0.64)
Retrospective
cohort
30-day mortality 0.54 (0.42e0.70)
Prospective
observation
30-day mortality 0.46 (0.25e0.85)
Retrospective
database
30 day mortality 0.69 (0.58e0.82)
1088 J.D. Chalmers et al.a prospectively collected database was published in the
BMJ in 2006. This study suggested that confounding due to
the “healthy user effect” may be responsible for the
observed benefits of statins. In this study by Majumdar
et al., prior statin use was assessed in a population of 3415
patients in 6 hospitals.91 In their “raw analysis” statin users
were less likely to die or be admitted to the intensive care
unit (although not statistically significant), but when these
results were adjusted using a propensity score, a statistical
technique to adjust for potential confounders, no signifi-
cant association was found. The authors conclude that
previous findings of benefit for statins were due to healthy
user bias- the theory that patients taking statins are also
more likely to do other beneficial health behaviours such
as taking pneumococcal and influenza vaccination or
stopping smoking that may be associated with better
outcome.92
The results of the study by Majumdar et al.,91 however,
are in variance with other studies.3,4,93 In the analysis by
Majumdar et al., older age and the presence of congestive
cardiac failure were found to be protective against poor
outcome.91 The converse has been consistently found in
other studies2e5,93 This may have arisen as the study by
Majumdar et al. used a combined outcome (mortality or
admission to an intensive care unit) rather than mortality
alone, or because of the use of a complex propensity score
in an attempt to adjust for confounders.91 Statin use is
strongly associated with age and underlying cardiac disease
and therefore the interaction between these factors is
difficult to interpret.
Following this, the present authors performed
a prospective study that aimed to account for these
factors.94 The study in the UK of 1269 patients found
a significant reduction in 30-day mortality in patients pre-
treated with statins. We attempted to account for healthy
user bias both by adjusting the multivariate analysis for
important confounders, but also by assessing the impact of
other cardiovascular drugs (ACE-Inhibitors/Angiotensin
converting enzyme receptor antagonists/Aspirin/b-
blockers). Our hypothesis was that the healthy user bias
would lead to an apparent benefit for all cardiovascular
drugs, not simply statins. No such association was found and
only statins were associated with reduced 30-day mortality
(OR 0.46, 95% confidence interval [CI], 0.25e0.85). Further,
complications of pneumonia (complicated parapneumonic
effusion and empyema) were reduced in statin users (AOR
0.44, 95% CI, 0.25e0.79) along with C-Reactive protein
levels.94 Cardiac events are common during acute pneu-
monia and risk is increased following episodes of pneu-
monia. It may be reasonably argued that statins exert their
effect through reduced cardiovascular events. The reduced
risk of complicated pneumonia in our study however,
suggest that an immunomodulatory effect could also be
responsible.38
We must also accept however, that no observational
study can fully adjust for all possible confounders.
A large study from Denmark published in 2008 provided
further confirmation of a significant reduction in pneumonia
mortality for patients prescribed statin treatment.95 This
analysis is significant, both because of the large sample size
and because of the detailed information collected about co-
morbidities and socioeconomic markers that allowed theauthors to account for potential “healthy user bias”. The
authors found a significant reduction in 30-day mortality
from CAP associated with statin use (OR 0.69 (0.58e0.82),
even after adjusting for a propensity score, which Majumdar
et al. had felt was a key feature of their study.
In sepsis, not limited to pneumonia, several further
studies have suggested a protective role for statins. The
study by Hackam et al. published in the Lancet in 2006
matched 34,584 statin treated patients with the same
number of non-statin users in an elderly population
following hospitalisation for acute cardiovascular events.96
The study was significant, because of the large sample size,
but also because the statin user and non user populations
were well matched for the majority of important potential
confounders, such as co-morbidities and residency status.
Statin use was associated with a reduced risk of sepsis
(Hazard ratio 0.81 95% CI 0.72e0.91) and a reduced risk of
fatal sepsis HR 0.75 (0.61e0.93). Such an effect was not
seen for non-statin lipid lowering therapy, which increases
the likelihood of a true biological effect rather than healthy
user bias.96 Studies by Fernandez et al.,97 Kruger et al.,98
Yang et al.,99 and Mortensen et al.,90 have produced con-
flicting results, but are limited by retrospective design and
the limited data available in some of these studies to adjust
for confounders.
Additional factors which should be considered include
the possibility that not all statins may have the full range of
beneficial effects, as illustrated by the experimental
studies of Erkilla,40 Tirola41 and Fessler39 discussed above.
The dose of statins required to produce a beneficial effect
has not been studied and the duration of prior treatment
required to produce a protective effect has not been
established in these observational studies.
The major studies describing outcomes for statin treat-
ment in hospitalised patients with pneumonia and sepsis
are described in Table 2.
The majority of studies demonstrate a beneficial effect
of statin therapy. The results of ongoing randomised
controlled trials are awaited. One randomised controlled
trial has recently been published. Novack and colleagues
randomised 83 patients with suspected bacterial infections
to simvastatin or placebo. Unfortunately the trial was
terminated due to slow recruitment, but a secondary anal-
ysis demonstrates a reduction in proinflammatory cytokines
(TNF-alpha and IL-6) in the statin treated group.103 Results
of larger trials powered to detect mortality benefit are now
awaited.
Observational studies show association rather than
causation and only data from randomised control trials will
establish conclusively if statins are effective in preventing
or treating CAP.Conclusion
Current evidence suggests that pretreatment with statins
may have a beneficial effect in prevention of pneumonia
and reducing severity of community acquired pneumonia.
Randomised controlled trials are needed to establish if
statins offer an innovative new adjunctive treatment to
antibiotics for patients admitted to hospital with commu-
nity acquired pneumonia.
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